Sarda Proteins Approves Significant Management Changes and Boosts Authorized Capital

Sarda Proteins Approves Significant Management Changes and Boosts Authorized Capital​

Sarda Proteins Ltd., during its Board meeting held on July 4, 2026, announced several major corporate restructuring events, including a significant increase in authorized equity share capital, changes in senior management appointments, and the resignation of key directors.

The Board Meeting reviewed and approved multiple critical operational and personnel changes for the company. These decisions cover increases to capital structure, alterations to the Memorandum of Association (MOA), and appointments within the executive team.

Key Personnel Appointments and Changes​

The board formalized several leadership transitions, including the appointment of a new Managing Director and the designation change of an existing senior executive.

Mr. Shirish Dhirajlal Savaliya was appointed as the Managing Director of Sarda Proteins for a period of five consecutive years, effective from July 4, 2026. Mr. Savaliya holds a Bachelor of Commerce degree from Saurashtra University and has over 16 years of experience in finance, accounting, business development, and strategic management.

Ms. Drashti Harshadbhai Delvadiya was appointed as the Chief Financial Officer (CFO) of the company, effective July 4, 2026. Ms. Delvadiya holds a Master of Commerce accredited by Saurashtra University and possesses over nine years of professional experience in Finance and Accounting.

Simultaneously, Mr. Yagnik Arvindbhai Satasiya’s designation was changed from Chief Financial Officer (CFO) to Additional Director (Non-Executive), with the capacity of Chairperson of the Company. This change is effective from July 4, 2026, or for a period of five consecutive years, subject to shareholder approval at the ensuing general meeting. Mr. Satasiya holds a Bachelor of Engineering in Electrical and has over nine years of experience in the industry, handling Business Development & Finance department.

The company also took note of the resignations of three directors: Bipinkumar Babubhai Savalia, Khilan Hareshbhai Savaliya, and Chintan Umeshbhai Bhatt, all effective from July 4, 2026.

A summary of the key personnel changes approved by the Board is provided in the table below:

Authorized Capital Increase​

The Board meeting also considered and approved a substantial increase in the company's authorized equity share capital. The capital was increased from ₹13,00,00,000 (Rupees Thirteen Crore Only), divided into 1,30,00,000 equity shares of ₹10 each, to ₹1,00,00,00,000 (Rupees Hundred Crore Only), which will be divided into 10,00,00,000 equity shares of ₹10 each.

Board and Committee Matters​

Furthermore, the Board approved the reconstitution of key committees, including the Audit Committee, Nomination and Remuneration Committee, and Stakeholders' Relationship Committee. The company also appointed a scrutinizer for the upcoming Extraordinary General Meeting (EGM) and approved the draft notice of the EGM.

Stock Price Movement​

Sarda Proteins Ltd. settled at ₹93.13 in post-market trading on Monday, registering zero change against its previous close. Throughout the day, the shares remained locked, as the stock traded completely flat within an intraday range of ₹93.13.